HF
BCAX

HRT Financial’s Bicara Therapeutics BCAX Stock Holding History

HRT Financial’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$799K Sell
40,209
-9,938
-20% -$171K ﹤0.01% 2197
2025
Q4 		$843K Buy
+50,147
New +$856K ﹤0.01% 1826

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

HRT Financial's BCAX Position: Q1 2026 in Review

HRT Financial reduced its Bicara Therapeutics (BCAX) stake by 20% in Q1 2026, selling an estimated $171K and leaving 40,209 shares worth $799K. The position accounts for ﹤0.01% of the portfolio, ranked #2197.

HRT Financial first reported a position in BCAX in Q4 2025 and has held it in 2 quarters since. The position peaked at $843K in Q4 2025. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • HRT Financial held 40,209 shares of Bicara Therapeutics worth $799K as of Q1 2026.
  • HRT Financial sold 9,938 Bicara Therapeutics shares in Q1 2026, an estimated $171K.
  • Bicara Therapeutics made up ﹤0.01% of HRT Financial's portfolio in Q1 2026, its #2197 holding.
  • HRT Financial first reported a position in Bicara Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • HRT Financial's Bicara Therapeutics position peaked at $843K in Q4 2025.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.